E-5-(2-chlorovinyl)-2′-deoxycytidine (CVDC) has been prepared for the first time using an improved synthesis of the starting material E-5-(2-chlorovinyl)-2′-deoxyuridine (CVDU). CVDC and CVDU were only slightly less active against herpes simplex virus type 1 (HSV-1) and varicella-zoster virus (VZV) than the potent anti-herpes compound E-5-(2-bromovinyl)-2′-deoxyuridine (BVDU). The Z-forms of CVDC and CVDU were markedly less active against HSV-1 and VZV than the E-isomers. None of the compounds showed activity against thymidine kinase (TK)-deficient variants of HSV-1.
Get full access to this article
View all access options for this article.
References
1.
BarrP.J.JonesA.S.VerhelstG., and WalkerR.T. (1981) Synthesis of some 5-halogenovinyl derivatives of uracil and their conversion into 2′-deoxynucleosides. J Chem Soc Perkin Trans1: 1665–1670.
2.
De ClercqE. (1984) Topical treatment of cutaneous herpes simplex virus infection in hairless mice with (E)-5-(2-bromovinyl)-2′-deoxyuridine and related compounds. Antimicrob Agents Chemother26: 155–159.
3.
De ClercqE. (1986) Towards a selective chemotherapy of virus infections. Development of bromovinyldeoxyuridine as a highly potent and selective antiherpetic drug. Verh K Acad Geneeskd Belg48: 261–290.
4.
De ClercqE., and WalkerR.T. (1984) Synthesis and antiviral properties of 5-vinylpyrimidine nucleoside analogs. Pharmac Ther26: 1–44.
5.
De ClercqE., and RosenwirthB. (1985) Selective in vitro and in vivo activities of 5-(2-haloalkyl)pyrimidine nucleoside analogs, particularly 5-(2-chloroethyl)-2′-deoxyuridine, against herpes simplex virus. Antimicrob Agents Chemother28: 246–251.
6.
De ClercqE.DescampsJ.De SomerP.BarrP.J.JonesA.S., and WalkerR.T. (1979) (E)-5-(2-Bromovinyl)-2′-deoxyuridine: a potent and selective anti-herpes agent. Proc Natl Acad Sci USA76: 2947–2951.
7.
De ClercqE.DescampsJ.VerhelstG.JonesA.S., and WalkerR.T. (1980a) Antiviral activity of 5-(2-halogenovinyl)-2′-deoxyuridines. In Current Chemotherapy and Infectious Disease. NelsonJ.D., and GrassiC. (eds). Washington, D.C.: American Society of Microbiology, pp. 1372–1374.
8.
De ClercqE.DescampsJ.VerhelstG.WalkerR.T.JonesA.S.TorrenceP.F., and ShugarD. (1980b) Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. J Inf Dis141: 563–574.
9.
De ClercqE.BalzariniJ.DescampsJ.HuangG.-F.TorrenceP.F.BergstromD.E.JonesA.S.SerafinowskiP.VerhelstG., and WalkerR.T. (1982) Antiviral, antimetabolic, and cytotoxic activities of 5-substituted 2′-deoxycytidines. Mol Pharmacol21: 217–223.
10.
De ClercqE.DesgrangesC.HerdewijnP.SimI.S.JonesA.S.McLeanM.J., and WalkerR.T. (1986a) Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine. J Med Chem29: 213–217.
11.
De ClercqE.HolyA.RosenbergI.SakumaT.BalzariniJ., and MaudgalP.C. (1986b) A novel selective broad-spectrum anti-DNA virus agent. Nature323: 464–467.
12.
DesgrangesC.RazakaG.RabaudM.BricaudH.BalzariniJ., and De ClercqE. (1983) Phosphorolysis of (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU) and other 5-substituted-2′-deoxyuridines by purified human thymidine phosphorylase and intact blood platelets. Biochem Pharmacol32: 3583–3590.
13.
DesgrangesC.RazakaG.DrouilletF.BricaudH.HerdewijnP., and De ClercqE. (1984) Regeneration of the antiviral drug (E)-5-(2-bromovinyl)-2′-deoxyuridine in vivo. Nucl Acids Res12: 2081–2090.
14.
DesgrangesC.RazakaG.De ClercqE.HerdewijnP.BalzariniJ.DrouilletF., and BricaudH. (1986) Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Cancer Res46: 1094–1101.
15.
JonesA.S.VerhelstG., and WalkerR.T. (1979) The synthesis of the potent anti-herpes virus agent, E-5-(2-bromovinyl)-2′-deoxyuridine and related compounds. Tetrahedron Lett, 4415–4418.
16.
ShigetaS.YokotaT.IwabuchiT.BabaM.KonnoK.OgataM., and De ClercqE. (1983) Comparative efficacy of antiherpes drugs against various strains of varicella-zoster virus. J Inf Dis147: 576–584.
17.
SungW.L. (1981) Chemical conversion of thymidine into 5-methyl-2′-deoxycytidine. J Chem Soc Chem Commun, 1089–1091.
